|
 |
Best Practices in SAS Statistical Programming in Regulatory Submission |
|
|
19-20 October 2009
Hoofddorp, The Netherlands
This intense two-day course focuses on the validation process to assure that correct, consistent and reliable summary tables are reproducible. In addition, a variety of effective methods for producing standard and custom summary tables will be provided. SAS data sets used in the course are CDISC ready. Discussions will focus on proven techniques to address real-world issues. Get your SAS technical and validation questions answered and learn efficient tips for producing a quality regulatory submission in a timely manner. Students will receive a CD containing all tools and SAS macros reviewed in the course.
This course is intended for anyone directly or indirectly responsible for the creation, content or validation of summary tables, data lists and graphs used to support research, drug or medical device efficacy and safety in a regulatory submission. Professionals in the pharmaceutical, biotechnology and medical device industries who want to be 21 CFR Part 11 compliant in relation to the SAS programming environment will benefit from this unique course. Effective and practical solutions to address real-world issues will be provided.
www.cfpa.com/200910192234-18a/2234/f/courseSummary.aspx |
|
|
|
|
|
 |
|
|
 |
Industry Events |
 |
Translational Neuroscience
27-28 October 2010, Ramada Frankfurt Messe
The treatment of neurological disorders has entered a new period of optimism. New insights into the underlying mechanisms of previously untreatable disorders, has led to a flurry of activity and a host of new drugs in development. However, the major bottleneck, and the biggest barrier to commercial exploitation, is clinical progression.
More info >> |
|
 |
News and Press Releases |
 |
ClinTec International
ClinTec International, a global Clinical Research Organisation (“CRO”) announces a financial and strategic partnership with Elephant Capital Plc., an AIM market listed private equity firm. With an investment of £8 Million GBP, Elephant has acquired a significant minority stake in ClinTec. Through this investment, Elephant has entered the attractive clinical research base, where ClinTec operates as a global provider of outsourcing solutions addressing the drug development lifecycle. Managing Partner of Elephant Capital LLP, Gaurav Burman, and Non-Executive Director of Elephant Capital Plc, James Hauslein, have also made personal co-investments in this transaction.
More info >> |
|
|
